Cyclophosphamide, Doxorubicin, and Cisplatin Combined in the Treatment of Advanced Sarcomas

John H. Edmonson, Richard G. Hahn, Allan J. Schutt, Harry F. Bisel, James N. Ingle

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Twenty‐five patients with evaluable histologically confirmed inoperable metastatic sarcomas were treated once every four weeks with cyclophosphamide, doxorubicin, and cisplatin in doses of 400, 40, and 60 mg/m2, respectively. Cyclophosphamide and doxorubicin were given by rapid intravenous injection followed immediately by cisplatin by slow intraveneous infusion (2‐6 hr) in 1 liter of 0.45% saline with mannitol added. Leukopenia, alopecia, and vomiting were common side effects and three patients refused further treatment because of vomiting following their initial courses. No drug‐related deaths occurred and we removed no one from the study because of toxicity problems. Among the 9 patients who experienced objective tumor regression were 2 of 2 with hemangio‐sarcoma, 3 of 5 with malignant fibrous histiocytoma, 3 of 5 with osteosarcoma, and 1 of 1 with pleomorphic liposarcoma of bone. Although not therapeutically gratifying, these results appear to be better than any previously observed at our institution.

Original languageEnglish (US)
Pages (from-to)319-321
Number of pages3
JournalMedical and Pediatric Oncology
Issue number5
StatePublished - 1983


  • cisplatin
  • cyclophosphamide
  • doxorubicin
  • sarcoma

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Cancer Research


Dive into the research topics of 'Cyclophosphamide, Doxorubicin, and Cisplatin Combined in the Treatment of Advanced Sarcomas'. Together they form a unique fingerprint.

Cite this